Tissue Microarray Detection of Estrogen Receptor, Progesterone Receptor, and C-erbB-2 in Patients with Ovarian Cancer and a Preliminary Study on the Molecular Typing of Ovarian Cancer

2020 ◽  
Vol 12 (10) ◽  
pp. 1159-1165
Author(s):  
Jian Wang ◽  
Dehua Liu ◽  
Yong Liu ◽  
Gongliang Zhang ◽  
Fang Peng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Expression Pattern ◽  
Molecular Typing ◽  
Expression Patterns ◽  
Double Positive ◽  
Cancer Subtypes ◽  
Er Expression

We evaluated the expression of estrogen receptor (ER), progesterone receptor (PR), and C-erbB-2 in patients with ovarian cancer using tissue microarrays (TMA) and preliminarily analyzed molecular typing data. Specimens from 119 ovarian cancer patients were collected and were analyzed by TMA. The expression of ER, PR, and C-erbB-2 was examined by IHC and the clinicopathological associations were analyzed. The results indicated that higher ER expression was observed in SC and EC, whereas PR exhibited a similar expression pattern, but relatively lower compared with ER expression. Conversely, very weak expression was observed in CCC and MC, especially for PR (All P <0.05). C-erbB-2 exhibited no expression pattern differences among the different histological types (All P >0.05), but exhibited higher positive expression in FIGO III and IV stages, whereas there was no difference in ER and PR expression among the different stages. Higher PR expression was observed in middle and highly differentiated tumors, whereas higher C-erbB-2 expression was associated with low degree of differentiation (P <0.05). Patients with ER (+) PR (+) C-erbB-2 (?) had a better prognosis and patients with ER (?) PR (?) C-erbB-2 (+) had the worst prognosis. In conclusion, ER and PR tend to be highly expressed in less malignant ovarian cancer subtypes such as SC and EC. Ovarian cancer patients with ER/PR double-positive and C-erbB-2 negative expression patterns survive longer.

Concurrent Endometrial Intraepithelial Carcinoma (EIC) and Serous Ovarian Cancer: Can EIC Be Seen as the Precursor Lesion?

2012 ◽  
Vol 22 (3) ◽  
pp. 457-464 ◽  
Author(s):  
Thijs Roelofsen ◽  
Léon C.L.T. van Kempen ◽  
Jeroen A.W.M. van der Laak ◽  
Maaike A. van Ham ◽  
Johan Bulten ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Expression Patterns ◽  
Neoplastic Progression ◽  
Precursor Lesion ◽  
Ki 67 ◽  
Cancer Management ◽  
Ploidy Analysis ◽  
Intraepithelial Carcinoma

ObjectiveThe pathogenesis of serous ovarian carcinoma (SOC) is still unknown. Recently, endometrial intraepithelial carcinoma (EIC) was proposed to be the precursor lesion of SOC. This study examines the model of EIC as precursor for SOC.MethodsCases of SOC with a noninvasive or superficially invasive serous lesion, a hyperplastic lesion with/without atypia, or EIC in the endometrium were selected for inclusion in this study. Tissue sections from both ovaries, the fallopian tubes, and the uterus were extensively reviewed by an expert gynecopathologist. For both EIC and SOC, immunostaining for p53, Ki-67, estrogen receptor, and progesterone receptor; TP53 mutation analysis; and in situ ploidy analysis were performed.ResultsNine cases of SOC with concurrent EIC in the endometrium were identified. Immunostaining for p53, Ki-67, estrogen receptor, and progesterone receptor revealed almost identical expression patterns and similar intensities in each pair of EIC and coincident SOC. Identical TP53 mutations were found in SOC and coinciding EIC in 33% of the cases, suggesting a clonal origin. DNA ploidy analysis, as a marker for neoplastic progression, demonstrated an increased number of aneuploid nuclei in SOC compared to their corresponding EIC (P = 0.039). In addition, the mean amount of DNA per nucleus in SOC was higher (ie, more aneuploid) compared to EIC (P = 0.039).ConclusionThis study provides a first indication of EIC as possible precursor lesion for SOC. This finding could have major clinical implications for future ovarian cancer management and underscores EIC as a possible target for early SOC detection and prevention.

scholarly journals Study on Estrogen Receptor, Progesterone Receptor and HER-2/ neu Expression Pattern by Immunohistochemistry in 87 cases of Invasive Breast Cancer

KYAMC Journal ◽  
2017 ◽  
Vol 5 (1) ◽  
pp. 436-443
Author(s):  
Md Shahadat Hossain ◽  
Ferdousy Begum ◽  
Ashim Ranjan Barua
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Expression Pattern ◽  
Invasive Breast Cancer ◽  
Standard Procedure ◽  
Low Grade ◽  
Positive Reactivity ◽  
Her 2 ◽  
Grade Tumour

Background: Now a day's determination of estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu expression pattern by immunohistochemistry in invasive breast cancer have become the standard procedure for breast cancer management.Objective: To see the expression pattern of estrogen receptor, progesterone receptor and HER-2/neu in Bangladeshi women with invasive breast carcinoma.Method: This cross sectional study was performed in 87 cases of invasive breast cancer. Estrogen receptor (ER), Progesterone receptor (PR) and HER-2/neu expression pattern were assessed by immunohistochemistry using monoclonal antibodies for detecting estrogen and progesterone receptors, and polyclonal antibody for detecting HER-2/neu.Results: All the cases were graded according to Bloom-Richardson grading system. Of those, Grade I tumour was 18 (20.69%), Grade II tumour was 58 (66.67%) and Grade III tumour was 11(12.64%). Both ER and PR positive reactivity were same and it was found 65 (74.71%) and HER-2/neu reactivity pattern were found negative in 59 (67.82%) cases and positive in 28 (32.18%) cases. A statistically significant correlation was found between the expression of ER and low grade tumour (p=0.011) and combined estrogen and progesterone receptor positive reactivity with low grade tumour (p=0.002).Conclusion: ER, PR and HER-2/neu expression do not correlated with each other, so it is recommended that each test should be independently determined by immunohistochemistry in all cases of invasive breast cancer. All equivocal cases of HER-2/neu (score 2+) should be analyzed by FISH technique to find out the percentage of real score.KYAMC Journal Vol. 5, No.-1, Jul 2014, Page 436-443

scholarly journals Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss

2013 ◽  
Vol 26 (9) ◽  
pp. 1161-1171 ◽  
Author(s):  
Lisa Braun ◽  
Friederike Mietzsch ◽  
Petra Seibold ◽  
Andreas Schneeweiss ◽  
Peter Schirmacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes ◽  
Receptor Signalling ◽  
Prognostic Relevance

scholarly journals Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Young-Joon Kang ◽  
Han-Byoel Lee ◽  
Yun Gyoung Kim ◽  
JaiHong Han ◽  
Yumi Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Prognostic Factor ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
End Point

Objective. While the value of Ki-67 has been recognized in breast cancer, controversy also exists. The goal of this study is to show the prognostic value of Ki-67 according to progesterone receptor (PgR) expression in patients who have estrogen receptor- (ER-) positive, human epidermal growth factor receptor 2- (HER2-) negative early breast cancer. Methods. The records of nonmetastatic invasive breast cancer patients who underwent surgery at a single institution between 2009 and 2012 were reviewed. Primary end point was recurrence-free survival (RFS), and secondary end point was overall survival (OS). Ki-67 and PgR were assessed with immunohistochemistry for the tumor after surgery. Results. A total of 1848 patients were enrolled in this study. 223 (12%) patients had high (≥10%) Ki-67, and 1625 (88%) had low Ki-67 expression. Significantly worse RFS and OS were observed in the high vs. low Ki-67 expression only when the PgR was low (<20%) (p<0.001 and 0.005, respectively, for RFS and OS). There was no significant difference in RFS and OS according to Ki-67 when the PgR was high (p=0.120 and 0.076). RFS of four groups according to high/low Ki-67 and PgR expression was compared. The low PgR and high Ki-67 expression group showed worst outcome among them (p<0.001). In a multivariate analysis, high Ki-67 was an independent prognostic factor when the PgR was low (HR 3.05; 95% CI 1.50–6.19; p=0.002). Conclusions. Ki-67 had a value as a prognostic factor only under low PgR expression level in early breast cancer. PgR should be considered in evaluating the prognosis of breast cancer patients using Ki-67.

scholarly journals Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16 -18F-Fluoro-17 -Estradiol PET/CT

2014 ◽  
Vol 56 (1) ◽  
pp. 50-55 ◽  
Author(s):  
M. van Kruchten ◽  
E. F. J. de Vries ◽  
H. J. G. Arts ◽  
N. M. Jager ◽  
A. H. H. Bongaerts ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Estrogen Receptor ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Receptor Expression ◽  
Estrogen Receptor Expression ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document